Bank of New York Mellon Corp Buys 15,211 Shares of Global Blood Therapeutics Inc (GBT)

Bank of New York Mellon Corp lifted its stake in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 6.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 236,471 shares of the company’s stock after purchasing an additional 15,211 shares during the period. Bank of New York Mellon Corp owned 0.46% of Global Blood Therapeutics worth $10,689,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its holdings in Global Blood Therapeutics by 1.9% in the first quarter. California State Teachers Retirement System now owns 59,314 shares of the company’s stock valued at $2,865,000 after acquiring an additional 1,115 shares during the last quarter. Sei Investments Co. lifted its holdings in Global Blood Therapeutics by 12.1% in the second quarter. Sei Investments Co. now owns 13,850 shares of the company’s stock valued at $626,000 after acquiring an additional 1,499 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in Global Blood Therapeutics by 4.4% in the first quarter. New York State Common Retirement Fund now owns 47,758 shares of the company’s stock valued at $2,307,000 after acquiring an additional 2,000 shares during the last quarter. Highland Capital Management LP lifted its holdings in Global Blood Therapeutics by 17.6% in the first quarter. Highland Capital Management LP now owns 16,000 shares of the company’s stock valued at $773,000 after acquiring an additional 2,400 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in Global Blood Therapeutics by 46.5% in the second quarter. Amalgamated Bank now owns 7,624 shares of the company’s stock valued at $345,000 after acquiring an additional 2,420 shares during the last quarter. Hedge funds and other institutional investors own 98.79% of the company’s stock.

In other news, Director Deval L. Patrick sold 42,379 shares of the company’s stock in a transaction on Friday, July 6th. The stock was sold at an average price of $43.40, for a total transaction of $1,839,248.60. Following the sale, the director now owns 15,000 shares of the company’s stock, valued at $651,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lesley Ann Calhoun sold 3,295 shares of the company’s stock in a transaction on Monday, July 9th. The stock was sold at an average price of $44.19, for a total value of $145,606.05. Following the sale, the insider now directly owns 1,388 shares in the company, valued at approximately $61,335.72. The disclosure for this sale can be found here. Insiders have sold 48,678 shares of company stock worth $2,128,844 in the last ninety days. Corporate insiders own 4.40% of the company’s stock.

NASDAQ:GBT opened at $40.40 on Tuesday. Global Blood Therapeutics Inc has a 52 week low of $27.55 and a 52 week high of $68.05. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -14.24 and a beta of 4.26.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings results on Thursday, August 2nd. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. During the same period last year, the firm earned ($0.55) EPS. sell-side analysts predict that Global Blood Therapeutics Inc will post -3.38 EPS for the current fiscal year.

GBT has been the topic of a number of recent analyst reports. SunTrust Banks set a $70.00 price objective on Global Blood Therapeutics and gave the company a “buy” rating in a report on Sunday, August 5th. JPMorgan Chase & Co. restated a “buy” rating and set a $75.00 price target on shares of Global Blood Therapeutics in a research note on Sunday, August 5th. Cantor Fitzgerald restated a “buy” rating and set a $96.00 price target on shares of Global Blood Therapeutics in a research note on Thursday, August 2nd. Zacks Investment Research upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Thursday, July 19th. Finally, Nomura upped their price target on Global Blood Therapeutics from $91.00 to $109.00 and gave the stock a “buy” rating in a research note on Thursday, June 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Global Blood Therapeutics currently has an average rating of “Buy” and a consensus price target of $80.53.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Featured Story: S&P 500 Index

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply